Tailored Radiofrequency Ablation of Uterine Myomas

International Evangelical Hospital54 enrolled

Overview

To perform the use of radiofrequency myolysis (RFM) for the treatment of intra-uterine fibroids through less invasive access by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy

Given that the RF ablation of solid tumors of the liver and other organs is successfully used as a usual approach, the investigators have decided to transfer this technology to an original treatment of uterine fibroids. The access to each individual fibroid was determined considering passage of the needle towards its centre through only compromised tissue and by the shortest possible route by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy. To optimize radiofrequency myolysis, in fact, the investigators decided to improve the procedure by inserting three innovative elements: application of a virtual needle tracking system to follow the RF electrode during the ablation session, real-time monitoring of RF ablation by contrast-enhanced ultrasound and systematic biopsy of the lesions before electro-coagulation.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Uterine Fibroids

Interventions

RADIOFREQUENCY ABLATION OF UTERINE MYOMASDEVICE

The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 62 YearsHealthy volunteers:

Medical Language ↔ Plain English

"Inclusion Criteria": * women who had symptomatic myomas with diameters ranging between 1.2 and 7.7 cm. - patients who had declined hysterectomy or laparoscopic myomectomy * submucosal fibroids with intramural extension ≥50% * intramural fibroids (FIGO G3 / G4 types) * subserosal fibroids (FIGO G5 / G6 types) "Exclusion Criteria": * Women with intracavitary (FIGO G0 / G1 types) or subserosal-pedunculated fibroids / (FIGO G7 types) * genital malignancy * cervical dysplasias * pelvic infection / adhesions * severe systemic diseases * pregnancy * deeply infiltrating endometriosis * patients who took gonadotropin-releasing hormone therapy or acetate ulipristal within 6 months

Locations (1)

International Evangelical Hospital

Genoa, Italy

Outcomes

Primary Outcomes

Myoma volumes after radiofrequency myolysis (RFM)

The outcomes evaluated after RFM were myoma volumes (cubic centimeters)

Time frame: 12 months

Myoma diameters after radiofrequency myolysis (RFM)

The outcomes evaluated after RFM were myoma diameters (centimeters)

Time frame: 12 months

Uterine Fibroid Symptom and Quality of Life (UFS-QOL) score after radiofrequency myolysis (RFM)

Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire with scores ranging from 0 to 100, were higher QOL scores mean a better health-related QOL 1 and a 10-point scale used for each reported symptom.

Time frame: 12 months

Secondary Outcomes

Surgical time of radiofrequency myolysis (RFM)

The surgical time (minutes) for each different type of surgical access

Time frame: 12 months

Surgical time of radiofrequency myolysis (RFM) assisted by new technologies

The reduction of surgical time (minutes) with the use of a virtual global positioning system (GPS) track system or a contrast-enhanced ultrasound during the ablation

Time frame: 12 months

Pre-intervention biopsy associated to radiofrequency myolysis (RFM)

The number of biopsies for treated fibroma

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.